Bone Morphogenetic Protein Signaling is a Possible Therapeutic Target in Gynecologic Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2022 Dec 5

PMID 36468782

Authors

Tomohiko Fukuda

Eri Suzuki

Risa Fukuda

Affiliations

Soon will be listed here.

Abstract

Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β (TGFβ) superfamily. BMPs play crucial roles in embryogenesis and bone remodeling. Recently, BMP signaling has been found to have diverse effects on different types of tumors. In this review, we summarized the effects of BMP signaling on gynecologic cancer. BMP signaling has tumor-promoting effects on ovarian cancer (OC) and endometrial cancer (EC), whereas it has tumor-suppressing effects on uterine cervical cancer (UCC). Interestingly, EC has frequent gain-of-function mutations in ACVR1, encoding one of the type I BMP receptors, which are also observed in fibrodysplasia ossificans progressiva and diffuse intrinsic pontine glioma. Little is known about the relationship between BMP signaling and other gynecologic cancers. Tumor-promoting effects of BMP signaling in OC and EC are dependent on the promotion of cancer stemness and epithelial-mesenchymal transition (EMT). In accordance, BMP receptor kinase inhibitors suppress the cell growth and migration of OC and EC. Since both cancer stemness and EMT are associated with chemoresistance, BMP signaling activation might also be an important mechanism by which OC and EC patients acquire chemoresistance. Therefore, BMP inhibitors are promising for OC and EC patients even if they become resistant to standard chemotherapy. In contrast, BMP signaling inhibits UCC growth in vitro. However, the in vivo effects of BMP signaling have not been elucidated in UCC. In conclusion, BMP signaling has a variety of functions, depending on the types of gynecologic cancer. Therefore, targeting BMP signaling should improve the treatment of patients with gynecologic cancer.

Citing Articles

Transcriptome profiling revealed multiple circadian rhythm-related genes associated with common gynecological cancers.

Peng L, Jiang M, Li K, Yu S, Zhao C, Zhang L Front Oncol. 2025; 15:1422122.

PMID: 39944833 PMC: 11813765. DOI: 10.3389/fonc.2025.1422122.

infection induces DNA double-strand breaks through the ACVR1/IRF3/POLD1 signaling axis to drive gastric tumorigenesis.

Xu X, Fei X, Wang H, Wu X, Zhan Y, Li X Gut Microbes. 2025; 17(1):2463581.

PMID: 39924917 PMC: 11812335. DOI: 10.1080/19490976.2025.2463581.

TGF-β superfamily-induced transcriptional activation pathways establish the RAD52-dependent ALT machinery during malignant transformation of MPNSTs.

Choi E, Lee J, Kim H, Kim Y, Kim S Sci Rep. 2024; 14(1):26475.

PMID: 39488637 PMC: 11531527. DOI: 10.1038/s41598-024-76732-z.

Hypoxia-driven M2-polarized macrophages facilitate the epithelial-mesenchymal transition of glioblastoma via extracellular vesicles.

Liu L, Wang R, Alifu A, Xiao Y, Liu Y, Qian C Theranostics. 2024; 14(16):6392-6408.

PMID: 39431006 PMC: 11488104. DOI: 10.7150/thno.95766.

The role of ncRNAs and exosomes in the development and progression of endometrial cancer.

Niebora J, Wozniak S, Domagala D, Data K, Farzaneh M, Zehtabi M Front Oncol. 2024; 14:1418005.

PMID: 39188680 PMC: 11345653. DOI: 10.3389/fonc.2024.1418005.

References

Bahador Zirh E, Tasar Kapakli E, Dolgun A, Usubutun A, Zeybek N . The expression of BMP, integrin, ZEB2 in ovarian high-grade serous carcinoma in relation with lymph node metastasis. Growth Factors. 2022; 40(3-4):153-162. DOI: 10.1080/08977194.2022.2099849. View

Shepherd T, Nachtigal M . Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology. 2003; 144(8):3306-14. DOI: 10.1210/en.2003-0185. View

Edson M, Nalam R, Clementi C, Franco H, DeMayo F, Lyons K . Granulosa cell-expressed BMPR1A and BMPR1B have unique functions in regulating fertility but act redundantly to suppress ovarian tumor development. Mol Endocrinol. 2010; 24(6):1251-66. PMC: 2875809. DOI: 10.1210/me.2009-0461. View

Fukuda T, Fukuda R, Miyazono K, Heldin C . Tumor Promoting Effect of BMP Signaling in Endometrial Cancer. Int J Mol Sci. 2021; 22(15). PMC: 8346149. DOI: 10.3390/ijms22157882. View

Mazzoldi E, Pavan S, Pilotto G, Leone K, Pagotto A, Frezzini S . A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer. Cell Death Dis. 2019; 10(6):412. PMC: 6538673. DOI: 10.1038/s41419-019-1656-4. View

Hsu Y, Gu F, Huang Y, Liu J, Ruan J, Huang R . Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res. 2013; 19(22):6272-85. PMC: 4080631. DOI: 10.1158/1078-0432.CCR-13-1734. View

Sato M, Kawana K, Fujimoto A, Yoshida M, Nakamura H, Nishida H . Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance. Oncol Rep. 2015; 35(1):391-7. DOI: 10.3892/or.2015.4367. View

Namkoong H, Shin S, Kim H, Ha S, Cho G, Hur S . The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer. 2006; 6:74. PMC: 1459871. DOI: 10.1186/1471-2407-6-74. View

Sinclair D, Mastroyannis A, Taylor H . Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. J Clin Endocrinol Metab. 2010; 96(2):412-21. PMC: 3048319. DOI: 10.1210/jc.2010-1450. View

10.

Theriault B, Shepherd T, Mujoomdar M, Nachtigal M . BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 2007; 28(6):1153-62. DOI: 10.1093/carcin/bgm015. View

11.

Roxburgh S, Murphy M, Pollock C, Brazil D . Recapitulation of embryological programmes in renal fibrosis--the importance of epithelial cell plasticity and developmental genes. Nephron Physiol. 2006; 103(3):p139-48. DOI: 10.1159/000092453. View

12.

McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S . Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011; 121(8):3206-19. PMC: 3148732. DOI: 10.1172/JCI45273. View

13.

Fadare O, Renshaw I, Liang S . Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues. Appl Immunohistochem Mol Morphol. 2011; 19(4):352-9. DOI: 10.1097/PAI.0b013e3182013441. View

14.

Grothey A, Galanis E . Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009; 6(9):507-18. DOI: 10.1038/nrclinonc.2009.110. View

15.

Chauvin M, Garambois V, Colombo P, Chentouf M, Gros L, Brouillet J . Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells. Sci Rep. 2021; 11(1):2231. PMC: 7838181. DOI: 10.1038/s41598-021-81819-y. View

16.

Laronda M, Unno K, Butler L, Kurita T . The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation. 2012; 84(3):252-60. PMC: 3443265. DOI: 10.1016/j.diff.2012.05.004. View

17.

Barbie T, Barbie D, MacLaughlin D, Maheswaran S, Donahoe P . Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003; 100(26):15601-6. PMC: 307614. DOI: 10.1073/pnas.2636900100. View

18.

Tsuchida R, Osawa T, Wang F, Nishii R, Das B, Tsuchida S . BMP4/Thrombospondin-1 loop paracrinically inhibits tumor angiogenesis and suppresses the growth of solid tumors. Oncogene. 2013; 33(29):3803-11. DOI: 10.1038/onc.2013.358. View

19.

Han H, Jain P, Resnick A . Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. Bone. 2017; 109:91-100. PMC: 7888549. DOI: 10.1016/j.bone.2017.08.001. View

20.

Kumari A, Shonibare Z, Monavarian M, Arend R, Lee N, Inman G . TGFβ signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021; 38(2):139-161. PMC: 7987693. DOI: 10.1007/s10585-021-10077-z. View